Od glucose (FBS) ( 110 mg/dL). Identifying MeS has several advantages. Some researchers con-sider MeS a multiple risk factor for CVD (8, 9) that its diagnosis will help treatment of important causes of CVD (10). However, there are those who disagree (11, 12). The role of MeS in the CHD in hemodialysis (HD) population has not been meticulously studied.2. ObjectivesThe aim of this study was to see whether MeS caused adverse cardiovascular events (CVEs) in patients on HD.3. Patients and MethodsCopyright ?2015, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.This study was conducted during March 2012 in four HD centers affiliated with Shahid Beheshti University of Medical Sciences, Tehran, Iran, and in two HD centers affiliated with Zanjan University of Medical Sciences, Zanjan, Iran. We studied the Win 63843 web presence of MeS in 300 patients on HD (173 males (57.7 ) and 127 females (42.3 )), with the mean ageof 61.7 ?14.2 years. In this study, MeS was defined according to ATP III criteria (8). The subjects were divided into two groups regarding presence of MeS criteria. All of the patients gave informed consent prior to data collection. Subjects were given a questionnaire to provide demographic data and medical histories. To assess CHD, we used the medical records of patients with chest pain and change of electrocardiogram (ECG), lab test, and wall motion abnormalities by ECG at cardiac care unit (CCU) admission. Moreover, serum predialysis blood urea nitrogen (BUN), creatinine (Cr), fasting blood sugar (FBS), hemoglobin (Hb), albumin (Alb), cholesterol, TG, phosphor (P), and calcium (Ca) were measured. The two groups’ measurements were compared. All examination and laboratory values were collected when the patients had reached their dry weight following the start of maintenance dialysis. In addition, waist circumference was measured at 1 cm above the umbilicus at the end of HD session. The subjects who were Chaetocin supplier administered antihypertensive medications were considered to have hypertension (HTN); the individuals who were administered antidiabetic medication were considered to have diabetes mellitus (DM). KT/V was used to evaluate the efficacy of dialysis. The level of blood pressure was recorded before and after HD. Duration of dialysis, age, and sex as well as the causes of ESRD were extracted from the patients’ medical records and were used for the final analysis. The HD protocol for all patients was four hours of using hemophane membrane with an average blood flow rate of 300 to 350 mL per minute and with bicarbonate-basis dialysate. The median duration of dialysis was 48 months (range, 12 to 192 month). Subjects were excluded if they were assumed to have a life expectancy of less than six months or unwilling to sign informed consent.Jalalzadeh M et al.had DM and 251 (83.7 ) had HTN. The participants’ general characteristics are presented in Table 1. The cause of ESRD in the subjects were as follows: HTN in 103 patients (34.3 ), diabetic nephropathy in 109 (36.3 ), chronic glomerulonephritis in 11 (3.6 ), polycystic kidney disease in 14 (4.7 ), urological problem in 9 (3 ), poisoning in 1 (0.33 ), autoimmune diseases in 3 (1 ), and idiopathic in 53 (17.7 ).T.Od glucose (FBS) ( 110 mg/dL). Identifying MeS has several advantages. Some researchers con-sider MeS a multiple risk factor for CVD (8, 9) that its diagnosis will help treatment of important causes of CVD (10). However, there are those who disagree (11, 12). The role of MeS in the CHD in hemodialysis (HD) population has not been meticulously studied.2. ObjectivesThe aim of this study was to see whether MeS caused adverse cardiovascular events (CVEs) in patients on HD.3. Patients and MethodsCopyright ?2015, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.This study was conducted during March 2012 in four HD centers affiliated with Shahid Beheshti University of Medical Sciences, Tehran, Iran, and in two HD centers affiliated with Zanjan University of Medical Sciences, Zanjan, Iran. We studied the presence of MeS in 300 patients on HD (173 males (57.7 ) and 127 females (42.3 )), with the mean ageof 61.7 ?14.2 years. In this study, MeS was defined according to ATP III criteria (8). The subjects were divided into two groups regarding presence of MeS criteria. All of the patients gave informed consent prior to data collection. Subjects were given a questionnaire to provide demographic data and medical histories. To assess CHD, we used the medical records of patients with chest pain and change of electrocardiogram (ECG), lab test, and wall motion abnormalities by ECG at cardiac care unit (CCU) admission. Moreover, serum predialysis blood urea nitrogen (BUN), creatinine (Cr), fasting blood sugar (FBS), hemoglobin (Hb), albumin (Alb), cholesterol, TG, phosphor (P), and calcium (Ca) were measured. The two groups’ measurements were compared. All examination and laboratory values were collected when the patients had reached their dry weight following the start of maintenance dialysis. In addition, waist circumference was measured at 1 cm above the umbilicus at the end of HD session. The subjects who were administered antihypertensive medications were considered to have hypertension (HTN); the individuals who were administered antidiabetic medication were considered to have diabetes mellitus (DM). KT/V was used to evaluate the efficacy of dialysis. The level of blood pressure was recorded before and after HD. Duration of dialysis, age, and sex as well as the causes of ESRD were extracted from the patients’ medical records and were used for the final analysis. The HD protocol for all patients was four hours of using hemophane membrane with an average blood flow rate of 300 to 350 mL per minute and with bicarbonate-basis dialysate. The median duration of dialysis was 48 months (range, 12 to 192 month). Subjects were excluded if they were assumed to have a life expectancy of less than six months or unwilling to sign informed consent.Jalalzadeh M et al.had DM and 251 (83.7 ) had HTN. The participants’ general characteristics are presented in Table 1. The cause of ESRD in the subjects were as follows: HTN in 103 patients (34.3 ), diabetic nephropathy in 109 (36.3 ), chronic glomerulonephritis in 11 (3.6 ), polycystic kidney disease in 14 (4.7 ), urological problem in 9 (3 ), poisoning in 1 (0.33 ), autoimmune diseases in 3 (1 ), and idiopathic in 53 (17.7 ).T.
